scRNAseq from in vitro mDA differentiation
This study has cells from differentiation protocols from human embryonic (hES)  and induced pluripotent (iPSC) stem-cells to midbrain dopaminergic neurons (mDA). These cells are engineered to ultimately be transplanted into patients with Parkinson's Disease (PD), which have a progressive degeneration of dopaminergic neurons (Zeng & Qin, 2022).  Three different protocols were tested. The protocol from Kriks et al (Kriks et al., 2011), labelled as UK; the same protocol with a boost that helps differentiation (CHIR)(Fujimori et al., n.d.) and a new protocol developed in Kyoto (JP). Also, four different cell lines were used, two UK clinical-grade embryonic stem-cells (ES)  cell lines, RC17 (Cellosaurus Cell Line RC-17 (CVCL_L206), n.d.) and Mshef7 (Cellosaurus Cell Line MasterShef7 (CVCL_BW80), n.d.), and two induced pluripotent stem cell (iPSC) lines 1231A3 (Cellosaurus Cell Line 1231A3 (CVCL_LJ39), n.d.) and 404C2 (Cellosaurus Cell Line 404C2 (CVCL_DP92), n.d.), where 404C2 is research-grade and 1231A3 is clinical-grade, already used in clinical trials. To study the differentiation over time, three different time points were taken: the initial one (0 days), after 16 days of differentiation, the time-point when cells are transplanted into patients in the clinical trials, and at 28 days of differentiation. Importantly all combinations performed were done with two replicates, to understand the reproducibility of such protocols.
This study has cells from differentiation protocols from human embryonic (hES)  and induced pluripotent (iPSC) stem-cells to midbrain dopaminergic neurons (mDA). These cells are engineered to ultimately be transplanted into patients with Parkinson's Disease (PD), which have a progressive degeneration of dopaminergic neurons (Zeng & Qin, 2022).  Three different protocols were tested. The protocol from Kriks et al (Kriks et al., 2011), labelled as UK; the same protocol with a boost that helps differentiation (CHIR)(Fujimori et al., n.d.) and a new protocol developed in Kyoto (JP). Also, four different cell lines were used, two UK clinical-grade embryonic stem-cells (ES)  cell lines, RC17 (Cellosaurus Cell Line RC-17 (CVCL_L206), n.d.) and Mshef7 (Cellosaurus Cell Line MasterShef7 (CVCL_BW80), n.d.), and two induced pluripotent stem cell (iPSC) lines 1231A3 (Cellosaurus Cell Line 1231A3 (CVCL_LJ39), n.d.) and 404C2 (Cellosaurus Cell Line 404C2 (CVCL_DP92), n.d.), where 404C2 is research-grade and 1231A3 is clinical-grade, already used in clinical trials. To study the differentiation over time, three different time points were taken: the initial one (0 days), after 16 days of differentiation, the time-point when cells are transplanted into patients in the clinical trials, and at 28 days of differentiation. Importantly all combinations performed were done with two replicates, to understand the reproducibility of such protocols.
University of Edinburgh